Biologic drug stability – ensuring quality and confidence for SOL-116
The complex journey of bringing a biologic to market – part 6 As SOL-116 progresses toward Phase II trials, stability...
Read the articleGrowing Together: Redefining CDMO Partnerships Through Trust and Communication
When we hosted the workshop “Growing Together: Navigating CDMO Partnerships Through Clinical Phases” at Nordic Life Science Days in Gothenburg,...
Read the articleFill & finish – Finalizing the product for clinical use
The complex journey of bringing a biologic to market – part 5 With GMP production of SOL-116 completed, the focus...
Read the articleExtracellular vesicles moving toward the clinic
Ola’s insights and future perspectives from ISEV 2025 Looking back to April this year, the world’s most renowned experts in...
Read the articleMoving into GMP – Turning process into product
The complex journey of bringing a biologic to market – part 4 The transition into GMP manufacturing marks a defining...
Read the articleOptimization of the isolation method for large-scale production of synthetic bacterial vesicles for cancer immunotherapy
Abstract Negar Ordouzadeh, Rossella Crescitelli, Agnes Zimmer, Petra Tjärnlund, Cecilia Lässer, Jan Lötvall, Kyong-Su Park Bacterial vesicles have emerged as therapeutic drug candidates to treat a...
Read the articleLinking the gap from development to robust manufacturing
The complex journey of bringing a biologic to market – part 3 It is a critical shift for companies when...
Read the articleViral vaccine manufacturing for clinical trials
Viral vaccines are entering a new era Vaccines have played a pivotal role in controlling infectious diseases for more than...
Read the articleAutomation advances for cell harvesting in biomanufacturing
In a recent article in BioPharm International, NorthX Biologics’ Agnes Zimmer and Erica Johansson explore how new technologies are revolutionizing...
Read the articleBridging innovation and execution: The critical role of technology transfer
The complex journey of bringing a biologic to market – part 2 The journey from early development to commercial production...
Read the articleWhy early CDMO collaboration matters in biologics development
The complex journey of bringing a biologic to market – part 1 Biologic drugs differ from traditional medicines as they...
Read the article